In the eligible population of 4,151,533 people aged 60 years or older, the discounted costs were $115,599,627 without vaccination and $130,566,196 with vaccination. Total deaths were 61,606 without vaccination and 57,204 with vaccination. Total discounted years of life lost were 138,070 without vaccination and 128,183 with vaccination.
The incremental cost per death averted with vaccination versus no vaccination was $3,400 (range -1,028 to 10,862). The incremental cost per life-year gained with vaccination was $1,514 (range -408 to 5,404).
If only cases of invasive pneumococcal disease were considered the incremental cost per life-year gained was $3,487. Most values were lower than the recommended cost-effectiveness threshold of the Colombian per capita gross domestic product, which was $4,799.
The most influential inputs were the vaccine efficacy against all-cause pneumonia, the cost of administration, the probability of all-cause pneumonia, the in-patient costs of pneumonia, and the probability of death due to all-cause pneumonia. At a willingness to pay of $1,500 per life-year gained, vaccination was cost-effective in over 50% of simulations.